Literature DB >> 10954518

Effect of the cytoplasmic domain of the simian immunodeficiency virus envelope protein on incorporation of heterologous envelope proteins and sensitivity to neutralization.

A N Vzorov1, R W Compans.   

Abstract

In addition to the viral envelope (Env) proteins, host cell-derived proteins have been reported to be present in human immunodeficiency virus and simian immunodeficiency virus (SIV) envelopes, and it has been postulated that they may play a role in infection. We investigated whether the incorporation of host cell proteins is affected by the structure and level of incorporation of viral Env proteins. To compare the cellular components incorporated into SIV particles and how this is influenced by the structure of the cytoplasmic domain, we compared SIV virions with full-length and truncated Env proteins. The levels of HLA-I and HLA-II molecules were found to be significantly (15- to 25-fold) higher in virions with full-length Env than in those with a truncated Env. Virions with a truncated Env were also found to be less susceptible to neutralization by specific antibodies against HLA-I or HLA-II proteins. We also compared the level of incorporation into SIV virions of a coexpressed heterologous viral glycoprotein, the influenza virus hemagglutinin (HA) protein. We found that SIV infection of cells expressing influenza virus HA resulted in the production of phenotypically mixed SIV virions containing influenza virus HA as well as SIV envelope proteins. The HA proteins were more effectively incorporated into virions with full-length Env than in virions with truncated Env. The phenotypically mixed particles with full-length Env, containing higher levels of HA, were sensitive to neutralization with anti-HA antibody, whereas virions with truncated Env proteins and containing lower levels of HA were more resistant to neutralization by anti-HA antibody. In contrast, SIV virions with truncated Env proteins were found to be highly sensitive to neutralization by antisera to SIV, whereas virions with full-length Env proteins were relatively resistant to neutralization. These results indicate that the cytoplasmic domain of SIV Env affects the incorporation of cellular as well as heterologous viral membrane proteins into the SIV envelope and may be an important determinant of the sensitivity of the virus to neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10954518      PMCID: PMC116329          DOI: 10.1128/jvi.74.18.8219-8225.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Molecular changes associated with replication of simian immunodeficiency virus in human cells.

Authors:  T Kodama; D P Burns; H W Kestler; M D Daniel; R C Desrosiers
Journal:  J Med Primatol       Date:  1990       Impact factor: 0.667

2.  The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus.

Authors:  D A Regier; R C Desrosiers
Journal:  AIDS Res Hum Retroviruses       Date:  1990-11       Impact factor: 2.205

3.  SIV adaptation to human cells.

Authors:  V M Hirsch; P Edmondson; M Murphey-Corb; B Arbeille; P R Johnson; J I Mullins
Journal:  Nature       Date:  1989-10-19       Impact factor: 49.962

4.  Use of infectious molecular clones of simian immunodeficiency virus for pathogenesis studies.

Authors:  H W Kestler; Y N Naidu; T Kodama; N W King; M D Daniel; Y Li; R C Desrosiers
Journal:  J Med Primatol       Date:  1989       Impact factor: 0.667

5.  The cytoplasmic domain of simian immunodeficiency virus transmembrane protein modulates infectivity.

Authors:  L Chakrabarti; M Emerman; P Tiollais; P Sonigo
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

6.  High-efficiency transformation of mammalian cells by plasmid DNA.

Authors:  C Chen; H Okayama
Journal:  Mol Cell Biol       Date:  1987-08       Impact factor: 4.272

7.  Characterization of infectious molecular clones of simian immunodeficiency virus (SIVmac) and human immunodeficiency virus type 2: persistent infection of rhesus monkeys with molecularly cloned SIVmac.

Authors:  Y M Naidu; H W Kestler; Y Li; C V Butler; D P Silva; D K Schmidt; C D Troup; P K Sehgal; P Sonigo; M D Daniel
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

8.  Selective radiolabeling of cell surface proteins to a high specific activity.

Authors:  J A Thompson; A L Lau; D D Cunningham
Journal:  Biochemistry       Date:  1987-02-10       Impact factor: 3.162

9.  Isolation of T-cell tropic HTLV-III-like retrovirus from macaques.

Authors:  M D Daniel; N L Letvin; N W King; M Kannagi; P K Sehgal; R D Hunt; P J Kanki; M Essex; R C Desrosiers
Journal:  Science       Date:  1985-06-07       Impact factor: 47.728

10.  Significance of premature stop codons in env of simian immunodeficiency virus.

Authors:  T Kodama; D P Wooley; Y M Naidu; H W Kestler; M D Daniel; Y Li; R C Desrosiers
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

View more
  11 in total

1.  Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles.

Authors:  Bao-Zhong Wang; Weimin Liu; Sang-Moo Kang; Munir Alam; Chunzi Huang; Ling Ye; Yuliang Sun; Yingying Li; Denise L Kothe; Peter Pushko; Terje Dokland; Barton F Haynes; Gale Smith; Beatrice H Hahn; Richard W Compans
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

2.  Truncating the gp41 Cytoplasmic Tail of Simian Immunodeficiency Virus Decreases Sensitivity to Neutralizing Antibodies without Increasing the Envelope Content of Virions.

Authors:  Ellen White; Fan Wu; Elena Chertova; Julian Bess; James D Roser; Jeffrey D Lifson; Vanessa M Hirsch
Journal:  J Virol       Date:  2018-01-17       Impact factor: 5.103

3.  "Cytoplasmic domain effects on exposure of co-receptor-binding sites of HIV-1 Env".

Authors:  Andrei N Vzorov; Richard W Compans
Journal:  Arch Virol       Date:  2016-08-03       Impact factor: 2.574

4.  Inactivation of human immunodeficiency virus type 1 by porphyrins.

Authors:  Andrei N Vzorov; Dabney W Dixon; Jenna S Trommel; Luigi G Marzilli; Richard W Compans
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

5.  Surface stability and immunogenicity of the human immunodeficiency virus envelope glycoprotein: role of the cytoplasmic domain.

Authors:  Ling Ye; Zhigao Bu; Andrei Vzorov; Dahnide Taylor; Richard W Compans; Chinglai Yang
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

6.  Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines.

Authors:  Ling Ye; Zhiyuan Wen; Ke Dong; Xi Wang; Zhigao Bu; Huizhong Zhang; Richard W Compans; Chinglai Yang
Journal:  PLoS One       Date:  2011-05-19       Impact factor: 3.240

7.  Activity of TAR in inducible inhibition of HIV replication by foamy virus vector expressing siRNAs under the control of HIV LTR.

Authors:  Jeonghae Park; Peter E Nadeau; Ayalew Mergia
Journal:  Virus Res       Date:  2009-01-09       Impact factor: 3.303

Review 8.  The antiviral activity of antibodies in vitro and in vivo.

Authors:  P W Parren; D R Burton
Journal:  Adv Immunol       Date:  2001       Impact factor: 3.543

9.  Role of the long cytoplasmic domain of the SIV Env glycoprotein in early and late stages of infection.

Authors:  Andrei N Vzorov; Armin Weidmann; Natalia L Kozyr; Vladimir Khaoustov; Boris Yoffe; Richard W Compans
Journal:  Retrovirology       Date:  2007-12-14       Impact factor: 4.602

10.  A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.

Authors:  Rogier W Sanders; Ronald Derking; Albert Cupo; Jean-Philippe Julien; Anila Yasmeen; Natalia de Val; Helen J Kim; Claudia Blattner; Alba Torrents de la Peña; Jacob Korzun; Michael Golabek; Kevin de Los Reyes; Thomas J Ketas; Marit J van Gils; C Richter King; Ian A Wilson; Andrew B Ward; P J Klasse; John P Moore
Journal:  PLoS Pathog       Date:  2013-09-19       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.